Personalized Medicine Forecast 2016 - Diaceutics
+

Personalized Medicine Forecast 2016



Steve Vitale
Peter Keeling
Mark Reis


A forecast for the industry raises some interesting points. Will there be 50 per cent more targeted therapy launches in 2016? Are labs becoming the key pharma launch partners? Are payer value models finally get some traction? And how will companion and complementary diagnostics be defined?

Listen to this webinar to learn:

  • Insights on the latest trends in targeted therapies
  • Best practices for your companion and complementary diagnostics launch
  • What you should be thinking about for your successful launch

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
EU IVD Regulation – What does it mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...
View all expert insights

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary
View all reports

Publications

TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a...
Challenges in the clinical implementation of precision medicine companion diagnostics
The pace of biomarker discovery has increased exponentially over the last few years,ushering in an era of precision medicine (PM) with a growing arsenal of treatments tailored to specific patient populations....
View all publications